NeurAxis preliminary Q4 revenue up 50% YoY to ~$800K; cash $3.7M

Neuraxis, INC

2024-FY EPS reported -$1.22 revenue$2,685,925

Preliminary Q4 2024 revenue ~$800K (+50% YoY); FY2024 revenue ~$2.7M (+11% YoY).
Cash balance as of Dec 31, 2024 was ~$3.7 million.
Insurance coverage expanded to ~45M lives, up from 4M a year ago.
FDA 510(k) clearance for IB-Stim expanded to ages 8-21; new CPT code for PENFS.
Commercialization of FDA-approved Rectal Expulsion Device (RED) begins Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.